TPOXX (tecovirimat) / SIGA Technologies - LARVOL DELTA

Myocarditis and Pericarditis as a Complication of Mpox: Case Series and Literature Review. (PubMed, Sex Transm Dis) - "Management of mpox involves symptom control and anti-inflammatories. Recent trials have not shown benefit of tecovirimat compared with placebo in shortening time to lesion resolution; however, in this article, we discuss nuances regarding antivirals in the setting of mpox-related myocarditis."

Journal • Review • Cardiovascular • Critical care • Infectious Disease • Inflammation • Pain

Fluorocarbyne Insertion into Benzene Skeletons. (PubMed, J Am Chem Soc) - "Pharmaceutical application to the antiviral agent tecovirimat yielded a fluorinated derivative with an approximately 3-fold increase in aqueous solubility. Mechanistic studies involving intermediate capture and DFT calculations support the fluorocarbyne intermediate and elucidate the origin of meta-insertion and the ring expansion pathway. This work presents the first application of metal-fluorocarbyne in organic synthesis, enabling concurrent fluorine incorporation and scaffold editing."

Journal

Characteristics of Inpatient Admission for Mpox Infection Control Isolation at 2 Large New York City Health Systems, 2022-2023. (PubMed, Public Health Rep) - "We found no significant differences in the median cumulative length of stay per patient or the proportion of tecovirimat receipt between the 2 groups. While the small size of the isolation cohort was a limitation of this analysis, our findings argue for increased capacity for community-based isolation, which may reduce the use of hospital admissions primarily for infection control isolation in future outbreaks."

Journal • Human Immunodeficiency Virus • Infectious Disease

Battle won, war ongoing: A call for mpox vaccination in high-risk dermatologic cases. (PubMed, JAAD Case Rep) - No abstract available

Journal

A diagnostic void in the Congo Basin: proposing a zoonotic orthopoxvirus as the cause of a hemorrhagic fever outbreak and a call for equitable health security. (PubMed, Infect Dis Poverty) - "The definitive etiology of the Basankusu outbreak remains unresolved, but the clinical and ecological evidence points toward a potential zoonotic origin consistent with known patterns of pathogen emergence in the Congo Basin. In a setting constrained by limited diagnostic capacity, such evidence-informed approach provides a pragmatic framework for immediate public health action-guiding the deployment of targeted diagnostics (pan-poxvirus PCR), therapeutics (tecovirimat), and vaccines (MVA-BN). Ultimately, preventing future outbreaks of diseases of poverty requires a global commitment to investing in local diagnostic capacity, sustainable development, and equitable health security within high-risk endemic regions like the Congo Basin."

Journal • Ebola Virus Disease • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease

Disseminated Mpox Infection in a Vaccinated Kidney Transplant Recipient (KIDNEY WEEK 2025) - "He was on a belatacept-based immunosuppressive regimen and has received Jynneos approximately two years prior to symptom onset...Given the severity of his lesions, he was treated with IV tecovirimat, vaccinia immune globulin (VIVIg), brincidofovir and topical cidofovir...Additional studies are needed to assess the effectiveness of these vaccines in immunocompromised patients. Figure 1: Perioral lesions before treatment (A) and after treatment ~2 months later (B), abdomen (C), right hand (D), and back lesions with typical desquamation (E)"

Clinical • Chronic Kidney Disease • Human Immunodeficiency Virus • Infectious Disease • Renal Disease • Transplantation

King Kong Pox: A Case of Severe Mpox and Bartonella Co-infection in a Patient Living With Human Immunodeficiency Virus (HIV). (PubMed, Cureus) - "While admitted, he completed a two-week course of IV tecovirimat, three doses of brincidofovir, and a single dose of VIGIV with gradual improvement and no new lesions. This case demonstrates the potential for Mpox to have a prolonged and extensive course with widespread necrotic ulcers in the setting of HIV despite treatment. It is critical to have timely diagnosis and treatment of both Mpox and underlying HIV, alongside management of co-infections for improving disease outcomes."

Journal • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • CD4

New aminoadamantane derivatives as inhibitors of F13 envelope protein from mpox virus. (PubMed, Biomed Pharmacother) - "A synergistic assay involving 3F2 and tecovirimat supported this finding, as no synergy was observed between 3F2 and tecovirimat, suggesting a common molecular target. All in all, AMA and especially 3F2 show robust activity against MPV, positioning them as promising options for antiviral therapeutic development vis-à-vis the emergency state of Mpox around the globe."

Journal • Infectious Disease

Combination of Mpox With Ocular Involvement, Human Immunodeficiency Virus, and Pulmonary Tuberculosis Resulting in High Mortality: A Report of Two Cases. (PubMed, Cureus) - "Despite treatment with tecovirimat, he died from respiratory failure...The risk of mpox fatality increases with HIV and TB co-infection. Early recognition of the disease signs may improve the prognosis."

Journal • Cognitive Disorders • Conjunctivitis • Human Immunodeficiency Virus • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Pain • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Re-emergence and clinical management of monkeypox: insights into viral biology, therapeutics, and vaccination. (PubMed, Mol Biol Rep) - "Antiviral therapies such as tecovirimat (TPOXX), cidofovir, and brincidofovir are under consideration, with tecovirimat showing the most clinical promise...Currently approved vaccines include ACAM2000, LC16 KMB, and JYNNEOS (MVA-BN), with JYNNEOS preferred due to its safety profile, especially for immunocompromised individuals and pregnant women. Preventive strategies, public education, and international surveillance are essential to mitigate further outbreaks. Understanding the biology, clinical behavior, and control measures of Mpox is critical for informing future responses and improving global preparedness."

Journal • Review • Fatigue • Infectious Disease • Musculoskeletal Pain • Pain

In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines. (PubMed, Clin Infect Dis) - "Of 17 clinical trials, 14 evaluated direct-acting antivirals; 86% focused solely on tecovirimat, a drug that shows safety but not efficacy with documented resistance concerns. Key vulnerable populations, including children, pregnant women, and people living with human immunodeficiency virus, remain absent from studies despite higher mortality rates. Our pipeline analysis revealed a fundamental mismatch between available countermeasures and actual needs, particularly in low-resource settings."

Journal • Human Immunodeficiency Virus • Infectious Disease

Cutaneous Mpox: an epidemiological, clinical, diagnostic and therapeutic review of the dermatologic pandemic of the decade. (PubMed, Ital J Dermatol Venerol) - "Cutaneous Mpox presents diagnostic and therapeutic challenges for dermatologists and venereologists, particularly when lesions deviate from classical patterns. Continued research on vaccine durability, combination antiviral therapies, and long-term cutaneous sequelae will refine future outbreak responses and patient care."

Journal • Dermatology • Hematological Disorders • Infectious Disease

Presence and Persistence of Monkeypox Virus DNA in Anatomic Sites and Body Fluids (ASTMH 2025) - "Fifty-three percent had received at least one dose of JYNNEOS vaccine and 40% received treatment with tecovirimat...Patients with mpox may shed virus in oral and rectal mucosa, saliva, and urine, although skin lesions appear to be the most persistent site of viral shedding. Severe immunosuppression may lead to significantly prolonged viral shedding from multiple sites and body fluids, though the frequency with which this occurs is unknown."

Human Immunodeficiency Virus • Infectious Disease • CD4

Brincidofovir in the Era of Mpox (ASTMH 2025) - "BCV moves intracellularly and is phosphorylated to cidofovir-diphosphate (CDV-PP), which then inhibits viral DNA polymerase activity. As reported from published cases, the use of BCV in 5 patients as a first-line treatment of clade II infections showed improved survival outcomes. Based on the mechanism of action of the drug, development of MPXV resistance to the viral DNA polymerase inhibitory activity of BCV is less likely to occur than with tecovirimat (TCV), which targets a viral surface protein. BCV has been demonstrated to be synergistic with TCV in vitro and in vivo in orthopoxviral infections."

Infectious Disease • Pediatrics

Pentacyclo-icosan-19'-one compound from Lawsonia inermis as monkeypox virus H1 phosphatase inhibitor: molecular docking, density functional theory, and molecular dynamics simulation studies. (PubMed, In Silico Pharmacol) - "The top three hit compounds exhibited binding affinities as low as - 8.2 kcal/mol, surpassing the positive controls, Antimycin A (- 6.1 kcal/mol) and Tecovirimat (- 7.0 kcal/mol)...These findings suggest that Lead 3 containing Lawsonia inermis, traditionally used for medicinal purposes, could be a potential source of antiviral agents against MPXV. This study provides a strong basis for further experimental validation and the development of novel therapeutic interventions against MPXV."

Journal • Infectious Disease

Mpox as a chronic active infection in a patient living with HIV/AIDS: clinical and virological implications in a year of evolution (EACS 2025) - "Tecovirimat was initiated (14-day course) alongside ART (TDF/3TC/DTG once daily). The final PCR-positive lesion was documented 14 months after symptom onset. Four samples collected during this period were sequenced, all belonging to clade IIb, lineage B.1.1 (Figure 2), indicating persistent infection rather than reinfection."

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Evaluating the advancements and efficacies in pharmacological Mpox treatments: a comprehensive review. (PubMed, Front Pharmacol) - "Prominent reviewed stewards include tecovirimat, brincidofovir, and cidofovir: drugs first developed for smallpox but repositioned for Mpox under expanded access programs. The review endorses increased clinical trial capacities, amended regulatory approaches development of new classes of therapeutics as part of global Mpox response efforts. By combining pharmacological breakthroughs with public health readiness, global health communities can be better equipped to respond to Mpox and other possible orthopox outbreaks of the future."

Journal • Review • Infectious Disease

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025. (PubMed, HIV Med) - "In 2025, the EACS Guidelines underwent a comprehensive update and restructuring. They now consist of two distinct parts and include several new sections. The recommendations are available as a free mobile app and in an interactive web format."

Journal • Breast Cancer • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Solid Tumor • Transplantation • Tuberculosis

Genomic variability and immunological aspects involved in response to MPXV infection. (PubMed, Front Pharmacol) - "Although smallpox vaccines like MVA-BN and ACAM2000 provide cross-protection against Mpox, the MVA-BN vaccine showed a more favourable safety profile, but variable effectiveness compared to replicating vaccines. Antiviral agents such as tecovirimat and cidofovir have been used off-label, but emerging resistance and limited clinical efficacy highlight an urgent need for MPXV-specific therapeutics...This review aims to provide a comprehensive overview of the molecular biology, clinical features, the current drugs used to treat Mpox infection and the vaccines used to prevent the infection. It also discussing the limitations of these therapeutic tools and the improvements needed to enhance their efficacy."

Journal • Review • Infectious Disease

Mpox: transmission dynamics, treatment, and innovations. (PubMed, Ther Adv Infect Dis) - "Current treatment strategies primarily involve supportive care, with advanced therapeutics such as tecovirimat, cidofovir, and brincidofovir reserved for severe cases. The emergence of drug-resistant strains, the persistence of mpox in vulnerable populations, and the potential for future outbreaks necessitate sustained investment in research and public health infrastructure. By integrating innovative therapeutic approaches, effective preventive measures, and comprehensive outbreak management strategies, the global health community can better address the ongoing threat of mpox and prepare for future public health challenges."

Journal • Review • Infectious Disease

Small molecule direct-acting antivirals for treatment of mpox. (PubMed, Antiviral Res) - "Two small molecule DAAs (tecovirimat and brincidofovir), approved by national regulatory agencies (e.g., U.S. FDA) for the treatment of smallpox based on efficacy in animal models, are in Phase 3 trials for mpox as of mid-2025. Additional DAAs for treatment of mpox are in early development, highlighting a major gap in medical countermeasures. Compound characteristics are identified that should increase the probability of clinical success and durability for mpox and improve the likelihood that they will also be effective against other ORPVs."

Journal • Review • Infectious Disease

Clinical Outcomes of Mpox Disease in Patients Treated with Tecovirimat. (PubMed, Clin Infect Dis) - "We described common reasons for tecovirimat initiation and hospitalization. There were racial inequities in hospitalization and treatment delays. More research and focused efforts to mitigate these inequities are needed. These findings may better inform decisions for treatment initiation and hospitalization for mpox."

Clinical data • Journal • Human Immunodeficiency Virus • Infectious Disease

Expanding the antiviral arsenal: N-arylated 1,2,4-oxadiazol-5(4H)-ones show high activity against orthopoxviruses. (PubMed, Eur J Med Chem) - "The synthesized derivatives showed activity higher than that of Cidofovir, although they were less effective than that of Tecovirimate. This work highlights the potential of oxadiazolone-based scaffolds as broad-spectrum antipoxviral agents that meet the unmet need for therapy against emerging and re-emerging orthopoxviral threats."

Journal

Tecovirimat for Severe Mpox Virus Infection in an Immunocompromised Patient. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Infectious Disease

Mpox Among Pregnant Women and Their Infants in the U.S. Outbreak, 2022-2023. (PubMed, Obstet Gynecol) - "In this descriptive report of pregnant and recently pregnant women with clade II mpox, there were no adverse maternal outcomes. Two neonates were diagnosed with mpox among 23 pregnancies with known outcomes. There were no reported adverse events related to tecovirimat administration in pregnant mothers."

Journal • Infectious Disease